within Pharmacolibrary.Drugs.ATC.L;

model L01AB01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 5.1666666666666664e-05,
    adminDuration  = 600,
    adminMass      = 0.8 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0005600000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00148,
    k12             = 4.6,
    k21             = 4.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01AB01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Busulfan is an alkylating agent that is used primarily as a chemotherapy drug for conditioning regimens prior to hematopoietic stem cell transplantation, especially in chronic myelogenous leukemia and other hematological malignancies. It is approved and in clinical use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients undergoing hematopoietic stem cell transplantation; intravenous administration.</p><h4>References</h4><ol><li><p>Lawson, R, et al., &amp; Hennig, S (2021). Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients. <i>Clinical pharmacokinetics</i> 60(1) 17–51. DOI:<a href=\"https://doi.org/10.1007/s40262-020-00947-2\">10.1007/s40262-020-00947-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33128207/\">https://pubmed.ncbi.nlm.nih.gov/33128207</a></p></li><li><p>Kikuchi, T, et al., &amp; Okamoto, S (2021). Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine. <i>International journal of hematology</i> 113(1) 128–133. DOI:<a href=\"https://doi.org/10.1007/s12185-020-02990-y\">10.1007/s12185-020-02990-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32886279/\">https://pubmed.ncbi.nlm.nih.gov/32886279</a></p></li><li><p>Locatelli, F, et al., &amp; Walters, MC (2022). Betibeglogene Autotemcel Gene Therapy for Non-β. <i>The New England journal of medicine</i> 386(5) 415–427. DOI:<a href=\"https://doi.org/10.1056/NEJMoa2113206\">10.1056/NEJMoa2113206</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34891223/\">https://pubmed.ncbi.nlm.nih.gov/34891223</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01AB01;
